Blog

Bribery & Corruption - “societal action v. unenforced regulation”

At the moment, the international approach to enforcement around bribery and corruption can seem uneven, at best and perhaps lax, at worst.

Read More

Topics: FCPA, Anti-Bribery and Anti-Corruption, third party risk management, Corruption Enforcement, Corruption, Fraud, Bribery, compliance programs, reputational risk, uk bribery, uk sfo

Speaking of Risk: Pharmaceutical Companies and Third Party Promotions

Pharmaceutical companies around the world are struggling to keep up with the rapid evolution of ethical frameworks around bribery and corruption in their industry.
Read More

Topics: Pharma, Anti-bribery & Anti-corruption, FCPA, Medical Companies, SEC, Corruption, Bribery, DOJ, teva, Pharmaceutical Companies, settlement, fines, gsk

What will 2017 Hold for Bribery & Corruption Enforcement?

8 reasons why anti-bribery & corruption compliance should be a focus for multinationals

If January is anything to go by, 2017 is set to be another year for headline-grabbing regulatory sanctions against organizations for bribery and corruption violations.  The year has already seen significant enforcement activity on both sides of the Atlantic.

Read More

Topics: Anti-Bribery and Anti-Corruption, third party risk management, Corruption Enforcement, Corruption, Global 2000, Fraud, Bribery, compliance programs